Page 23 - Read Online

Page 12 of 12 Nishioka et al. Hepatoma Res 2018;4:1 I http://dx.doi.org/10.20517/2394-5079.2017.46

23. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, Wagner SN, Ramaswamy S, Mesirov JP, Hynes RO. Gene expression
changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008;6:760-9.
24. Wong LL, Naugler WE, Schwartz J, Scott DL, Bhattacharya R, Reyes J, Orloff SL. Impact of locoregional therapy and alpha-fetoprotein
on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis. Clin Transplant 2013;27:E72-9.
25. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov
JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S
A 2005;102:15545-50.
26. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D, Bioulac-Sage
P, Laurent-Puig P, Zucman-Rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Hepatology 2007;45:42-52.
27. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival
in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76.
28. Galmiche A, Sauzay C, Chevet E, Pluquet O. Role of the unfolded protein response in tumor cell characteristics and cancer outcome.
Curr Opin Oncol 2017;29:41-7.
29. Houessinon A, Gicquel A, Bochereau F, Louandre C, Nyga R, Godin C, Degonville J, Fournier E, Saidak Z, Drullion C, Barbare JC,
Chauffert B, Francois C, Pluquet O, Galmiche A. Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis
in hepatocellular carcinoma cells exposed to sorafenib. Cancer Lett 2016;370:242-9.
30. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, Dynlacht BD. E2F integrates cell cycle progression with DNA repair,
replication, and G(2)/M checkpoints. Genes Dev 2002;16:245-56.
31. Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnu L, Zoli M, Borzio F, Caturelli E,
Chiaramonte M, Trevisani F. Low alpha-fetoprotein HCC and the role of GGTP. Int J Biol Markers 2014;29:e395-402.
32. Goossens N, Hoshida Y. Personalized management of hepatocellular carcinoma based on molecular information: future prospects. Clin
Liver Dis (Hoboken) 2015;5:132-5.
33. Finn RS, Aleshin A, Dering J, Yang P, Ginther C, Desai A, Zhao D, von Euw E, Busuttil RW, Slamon DJ. Molecular subtype and response
to dasatinib, an Src/Abl small molecule kinase inhibitor, in hepatocellular carcinoma cell lines in vitro. Hepatology 2013;57:1838-46.
34. Lee JS, Thorgeirsson SS. Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular
cancer. Hepatology 2002;35:1134-43.
35. Zyla J, Marczyk M, Weiner J, Polanska J. Ranking metrics in gene set enrichment analysis: do they matter? BMC Bioinformatics
2017;18:256.
36. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura H, Yamamoto S,
Shinbrot E, Hama N, Lehmkuhl M, Hosoda F, Arai Y, Walker K, Dahdouli M, Gotoh K, Nagae G, Gingras MC, Muzny DM, Ojima H,
Shimada K, Midorikawa Y, Goss JA, Cotton R, Hayashi A, Shibahara J, Ishikawa S, Guiteau J, Tanaka M, Urushidate T, Ohashi S, Okada
N, Doddapaneni H, Wang M, Zhu Y, Dinh H, Okusaka T, Kokudo N, Kosuge T, Takayama T, Fukayama M, Gibbs RA, Wheeler DA,
Aburatani H, Shibata T. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 2014;46:1267-73.